Dr. Jonathan Tward from University of Utah argued that surgical treatment should not be used as the standard of care for locally advanced SCC. Indeed, guidelines for a variety of SCC ranging from the lung to the vulva all use combined chemoradiation as first line treatment, with surgery reserved for the salvage setting. To demonstrate the efficacy of radiotherapy, Dr. Tward cited data presented at SUO 2016 correlating survival improvement in pelvic node positive patients with the use of postsurgical adjuvant radiation. Additionally, three successful anecdotes of unimodal radiotherapy for T2 penile SCC were used to illustrate curative potential. Dr. Tward ended by recounting the work of Norman Nigro and the shift from surgical to combination therapy for anal cancer. Although promising, this novel therapy needs to be validated in trial setting.
Presenter: Vitaly Margulis, MD, University Texas Southwestern, Jonathan T. Ward, MD, University of Utah
Written By: Roger Li, MD, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA